ଓଲୋପାଟାଡାଇନ

ଓଲୋପାଟାଡାଇନ
Clinical data
Trade names	Patanol and others
AHFS/Drugs.com	monograph
MedlinePlus	a602025
data	EU EMA: yes; US DailyMed: Olopatadine;
Pregnancy; category	C;
Routes of; administration	Eye drops, nasal spray
Legal status
Legal status	US: ℞-only / OTC;
Pharmacokinetic data
Elimination half-life	3 hours
Identifiers
	IUPAC name {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-; dihydrodibenzo[b,e]oxepin-2-yl}acetic acid;
Chemical and physical data
Formula	C21H23NO3
Molar mass	୩୩୭.୪୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3;
	InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- ; Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N ;
(verify)

ଓଲୋପାଟାଡାଇନ

ଓଲୋପାଟାଡାଇନ ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆଲର୍ଜି ଜନିତ କଞ୍ଜକ୍ଟିଭାଇଟିସ୍ ଏବଂ ଆଲର୍ଜିକ ନାକ ପ୍ରଦାହ/ ରାଇନାଇଟିସର ଲକ୍ଷଣ ହ୍ରାସ କରିବାକୁ ବ୍ୟବହୃତ ହୁଏ | ^[୨] ଏହା ବୁନ୍ଦା ଆକାରରେ ଆଖିରେ ଓ ନାକରେ ସ୍ଟ୍ରେ ଆକାରରେ ବ୍ୟବହୃତ ହୁଏ | ^[୩] ଆଖିର ଲକ୍ଷଣମାନ ସାଧାରଣତଃ ଅଧ ଘଣ୍ଟା ମଧ୍ୟରେ ଉନ୍ନତି କରେ | ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଗଳା ଯନ୍ତ୍ରଣା, ଆଖିରେ ଅସୁବିଧା ଏବଂ ସ୍ୱାଦର ପରିବର୍ତ୍ତନ ଅନ୍ତର୍ଭୁକ୍ତ | ^[୪] ^[୨] ଅଧିକ ଗୁରୁତ୍ୱପୂର୍ଣ୍ଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରା ପ୍ରଭାବିତ ହୋଇପାରେ | ^[୩] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର ସୁରକ୍ଷିତ କି ନାହିଁ ତାହା ଅସ୍ପଷ୍ଟ ରହିଛି। ^[୫] ଏହା ଏକ ଆଣ୍ଟିହିଷ୍ଟାମିନ ଓ ମାଷ୍ଟ ଜୀବକୋଷ ସ୍ଟାବିଲାଇଜର ।^[୬] ^[୩]

୧୯୮୬ ମସିହାରେ ଓଲୋପାଟାଡାଇନ ପେଟେଣ୍ଟ ହୋଇଥିଲା ଏବଂ ୧୯୯୭ ମସିହାରେ ଚିକିତ୍ସା ବ୍ୟବହାରରେ ଆସିଥିଲା ^[୭] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ଆଖି ଔଷଧର ଏକ ୫ ମିଲିଲିଟର ବୋତଲ ନିମନ୍ତେ ଏନଏଚଏସକୁ ୨୦୧୯ ମସିହାରେ ୫ ପାଉଣ୍ଡରୁ କମ ମୁଲ୍ୟ ଦେବାକୁ ପଡ଼େ ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ $ ୧୨.୫୦ ଅଟେ। ^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୧୭ ମସିହାରେ ଏହା ୨୭୦ତମ ସାଧାରଣତ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଏକ ମିଲିୟନରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ହୋଇଥିଲା | ^[୯] ^[୧୦]

ଆଧାର[ସମ୍ପାଦନା]

↑ "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. This article incorporates text from this source, which is in the public domain.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
↑ ^୪.୦ ^୪.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
↑ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Retrieved 26 March 2019.
↑ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 6 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. PMID 26028608.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 549. ISBN 9783527607495.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Olopatadine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[FDA_switch-1] "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. This article incorporates text from this source, which is in the public domain.

[AHFS2019-2] ୨.୦ ^୨.୧ ^୨.୨ "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.

[autogen3-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.

[BNF76-4] ୪.୦ ^୪.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.

[5] "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Retrieved 26 March 2019.

[Cas2015-6] Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 6 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. PMID 26028608.

[Fis2006-7] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 549. ISBN 9783527607495.

[NADAC2019-8] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-9] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-10] "Olopatadine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]